Adults 11 to 14, any sex, with Risk-Taking or Adolescent Behavior. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Changes in Emotional RegulationPrimary· 18 weeks (from pre-intervention to 3-months after post-intervention)
Emotional regulation was assessed through parent and youth self-reported questionnaires using the Behavior Rating Inventory of Executive Function, Second Edition (BRIEF-2). T scores, normed for age and sex are available. T-score standardizes an individual's executive functioning difficulties relative to peers. For example, 50 is the population mean and a standard deviation of 10. Higher scores indicate more significant problems. Scores below 60 are within normal limits; 60-64: subclinical difficulties; 65-69: mildly elevated; 70-74: moderately elevated; and 75 or above: considered highly eleva
Pre-intervention (baseline)
Group
Value
95% CI
Pathways for African-Americans' Success
54.43
± 12.23
Wait-list
52.02
± 10.15
Post-intervention (3-month follow-up after 6-week intervention)
Group
Value
95% CI
Pathways for African-Americans' Success
54.47
± 13.74
Wait-list
60.77
± 16.76
Changes in Cognitive RegulationSecondary· 18 weeks (from pre-intervention to 3-months after post-intervention)
Cognitive regulation was assessed through parent and youth self-reported questionnaires using the Behavior Rating Inventory of Executive Function, Second Edition (BRIEF-2). T scores, normed for age and sex are available. T-score standardizes an individual's executive functioning difficulties relative to peers. For example, 50 is the population mean and a standard deviation of 10. Higher scores indicate more significant problems. Scores below 60 are within normal limits; 60-64: subclinical difficulties; 65-69: mildly elevated; 70-74: moderately elevated; and 75 or above: considered highly eleva
Pre-intervention (baseline)
Group
Value
95% CI
Pathways for African-Americans' Success
55.41
± 10.71
Wait-list
54.51
± 10.52
post-intervention (3-month follow-up after intervention)
Group
Value
95% CI
Pathways for African-Americans' Success
51.81
± 20.94
Wait-list
55.66
± 18.44
Sponsor's own description
Adolescence is a time of biological and behavioral changes that can lead to risky and dangerous behaviors, and African-American youth are highly vulnerable to the consequences of risky behavior, including HIV/AIDS and violence, leading to premature death. The investigators previously showed that an intervention program reduces HIV-risk vulnerability behaviors in many African-American youth. The investigators aim to measure how the program affects different regions of the brain in order to better prevent or reduce such risky behaviors among African-American youth.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Irvine
Last refreshed: 26 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03370393.